A 12-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Multicenter Long-Term Safety Study of MK0928 in the Treatment of Elderly Outpatients With Primary Insomnia

NCT00095043 Phase 3 COMPLETED

The purpose of this trial is to study the safety of MK0928 on insomnia in the elderly.

Details

Lead sponsor	H. Lundbeck A/S
Phase	Phase 3
Status	COMPLETED
Enrolment	320
Start date	2004-10

Conditions

• Insomnia

Interventions

• MK0928, gaboxadol
• Comparator: placebo

Primary outcomes

• Safety and tolerability after 12 months of treatment